My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
11/01/2022 Meeting Minutes
Document-Host
>
City North Olmsted
>
Minutes
>
2022
>
11/01/2022 Meeting Minutes
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
11/16/2022 2:08:05 PM
Creation date
11/16/2022 1:55:38 PM
Metadata
Fields
Template:
North Olmsted Legislation
Legislation Date
11/1/2022
Year
2022
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
48
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
Show annotations
View images
View plain text
DEPARTMENT 00 HEI PlI & IICIII AA SERCICES Of 1,11 I 011,5 ;retay <br />A -nL Ito OL U20i <br />AUG 1 6 2018 <br />the I Ionorable tIttant Dinllon <br />Acting Administrator <br />Drug Enforcement Administration <br />II.S. Department )I JUSticc <br />8'01 Morrissette Drive <br />Springfield, A"A 221 �? <br />Dear Mr. Dhillon <br />Pursuant to the Controlled Substances Act (CSA), 21 LT S.0 @ 81 I, I am rescinding our prior <br />recommendation dated October 17, 2011, that the suhstances mitragynine and -- <br />hydroxvmitragPnine he perntancn0y controlled in Schedule 1 or the CSA. HHS is instead <br />recommending that mitmgynine and 7-hydroxymitragynine not be controlled at this time, either <br />temporarily orpermanently, until scientific research can sufficiently support such an action. <br />Mitragynine, and 7-OH-mitragynine are two of the constituents of the plant Milragyna speciosa <br />(M. speciosa), commonly referred to as kratom. This decision is based on many factors, in part <br />on new data, and in part on the relative lack of evidence, combined with an unknown and <br />potentially substantial risk to public health if these chemicals were scheduled at this time. <br />Further research, which I am proposing be undertaken, should provide additional data to better <br />inform any subsequent scheduling decision. <br />Procedural Hilton <br />On August 31, 2016, the Drug Enforcement Administration (DLA) isnuud a Nou.cot Intent III <br />temporarily schedule the chemicalk mitragvnine and 7-hvdroxNrni iagvnine into Schedule I <br />pursuant to the tempo in, scheduling provision..' of the CSA, 21 1 S,( � 811(h) Sce SI Fed - <br />Reg. 59,929 (:Aug. 31, IOIli)_ In response to the Notice of Intent, the DFA received uumernus <br />comments from the public on mitragvnine and' -h edroxvmiu'agrnine, including comments <br />offering Their opinions cgarcling the Pharmacological eLCTI of t11111 4LIh3tanee5. 10 allmc <br />amsider nI0u of these connnents. as hell us others received on or hefore Decmuber 1.1_0IF_ the <br />DHA issued n Withdratcal of Not cc of Intent and Solicitafion ofComments int Octnher 3I. <br />2016, <br />On October I 2n 17. the then- \ct:ii" A—MLI'll Secretin- tnr I Iealth of MIS hcrote to then- <br />Ading Adminislrulor of the DFA u, indicate that HIIS las reconunending that the suhstances <br />mi traevnitle and 7-0ii-mitragvnine he pcintenemk vntrolled in Schedule I of the Controlled <br />
The URL can be used to link to this page
Your browser does not support the video tag.